Central Cancer Registry Reporting Content IG, published by HL7 International / Public Health. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-central-cancer-registry-reporting-ig/ and changes regularly. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: Cancer Related Medication Administration - Example - JSON Representation

Raw json | Download

{
  "resourceType" : "MedicationAdministration",
  "id" : "cancer-med-admin-docetaxel-example",
  "meta" : {
    "profile" : [
      🔗 "http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-administration"
    ]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Profile: </b> <a href=\"https://hl7.org/fhir/us/mcode/StructureDefinition-mcode-cancer-related-medication-administration.html\">mCODE Cancer Related Medication Administration</a></p><p><b>status:</b> completed</p><p><b>category:</b> Outpatient</p><p><b>medication:</b> rxnorm 72962 docetaxel</p><p><b>subject:</b> <a href=\"Patient-example.html\">Patient-example: Amy Shaw</a></p><p><b>start date:</b> 2023-04-10</p><p><b>Performer:</b> Joseph Nichols</p><p><b>reasonReference:</b> Condition-primary-cancer-condition-breast</p><p><b>authoredOn:</b> 2023-04-10</p><p><b>note:</b> Chemotherapy regimen of docetaxel, carboplatin, adriamycin, cyclophosphamide, and paclitaxel administered by continuous infusion. Patient tolerated infusion without side effects.</p><p><b>Route:</b> SNOMED 47625008 Intravenous route (qualifier value)</p></div>"
  },
  "status" : "completed",
  "category" : {
    "coding" : [
      {
        "system" : "http://terminology.hl7.org/CodeSystem/medication-admin-category",
        "code" : "outpatient"
      }
    ]
  },
  "medicationCodeableConcept" : {
    "coding" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "code" : "72962",
        "display" : "docetaxel"
      }
    ]
  },
  "subject" : {
    🔗 "reference" : "Patient/example"
  },
  "effectiveDateTime" : "2023-04-10",
  "performer" : [
    {
      "actor" : {
        🔗 "reference" : "Practitioner/1"
      }
    }
  ],
  "reasonCode" : [
    {
      "coding" : [
        {
          "system" : "http://snomed.info/sct",
          "code" : "408643008",
          "display" : "Infiltrating duct carcinoma of breast (disorder)"
        }
      ]
    }
  ],
  "reasonReference" : [
    {
      🔗 "reference" : "Condition/primary-cancer-condition-breast"
    }
  ],
  "note" : [
    {
      "authorReference" : {
        🔗 "reference" : "Practitioner/1"
      },
      "time" : "2023-04-10",
      "text" : "docetaxel administered by continuous infusion. Patient tolerated infusion without side effects."
    }
  ],
  "dosage" : {
    "route" : {
      "coding" : [
        {
          "system" : "http://snomed.info/sct",
          "code" : "47625008",
          "display" : "Intravenous route (qualifier value)"
        }
      ]
    },
    "dose" : {
      "value" : 60,
      "unit" : "mg",
      "system" : "http://unitsofmeasure.org",
      "code" : "mg"
    }
  }
}